Novo Nordisk ranks 4th among the world's top 20 science employers

Novo NordiskNovo Nordisk was just ranked number four on the Science 2012 Top Employer list - up from ninth place last year. The company's 'social responsibility', 'respect for employees' and ability to inspire 'loyalty among its employees' were cited as key drivers of this impressive global ranking.

"We're proud to have jumped to the top five in this widely-recognised ranking of the world's best science employers. Our excellent researchers around the world are the main source of this company's strong innovation. The fact that they feel respected and take pride in working for a company that operates in a sustainable way is great to see. In the battle to recruit the best researchers, there's nothing more powerful than peer-to-peer communication," says Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk.

R&D professionals at Novo Nordisk comprise world-class experts in the engineering, expression, formulation and delivery of therapeutic proteins, as well as in the development of compounds into safe, effective and convenient treatment options for people living with chronic conditions like diabetes, haemophilia and rheumatoid arthritis. More than 4,000 employees work in Novo Nordisk R&D in Denmark, US, China and India.

"This positive evaluation of Novo Nordisk resonates well with my own personal experience as a diabetes researcher in the company for the past 21 years. Our collaborative work in multidisciplinary teams both within and outside of the company, and our openness to explore new ideas inspire me. It gives me the confidence that I'm part of a highly-qualified team working every day to find better treatment solutions for people with diabetes," says Erica Nishimura, scientific director of Diabetes Biology at Novo Nordisk.

In the Science 2012 survey, 4,276 employees working in the biotechnology, biopharmaceutical, pharmaceutical and related industries were asked to rank the 20 best employers based on 23 characteristics, including research-driven environment and financial strength.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...